The decision, issued without the input of an official advisory committee, revises long-held labeling on the drugs cautioning ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

Analysts suspected that the mid-stage trial miss wouldn't ding Neurocrine’s share price since expectations around the program were "near-zero." ...

Merck’s pill, which could be the first oral PCSK9 drug to get to market, displayed similar effects on lipid levels as ...

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...